Deletions and point mutations of EED, EZH2, and SUZ12 are found in 42% of early T-cell precursor (ETP) ALL cases, as well as in 12% of T-cell ALL cases in non-ETP malignancies [23]. This evidence concerns the gene EZH2 and acute lymphoblastic leukemia.